卡格列净
医学
安慰剂
内科学
糖化血红素
不利影响
养生
2型糖尿病
2型糖尿病
糖尿病
血压
临床终点
内分泌学
甘油三酯
随机对照试验
胃肠病学
胆固醇
替代医学
病理
作者
Bruce W. Bode,Kaj Stenlöf,Daniel J. Sullivan,Albert Fung,Keith Usiskin
标识
DOI:10.3810/hp.2013.04.1020
摘要
Canagliflozin improved glycemic control, reduced body weight and systolic BP, and was generally well tolerated in older subjects with T2DM who were on background therapy with a variety of blood glucose-lowering agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI